Sareeta Parker

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 658 citations · Full text

Medicine, Dermatology, Oncology +17

Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States

Sareeta Parker, Senait W. Dyson, Stacey Brisman et al. · Journal of the American Academy of Dermatology · 2008 · 107 citations

Public Health, Population Health Sciences, Clinical Epidemiology +3

Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma

Madeleine Duvic, Elise A. Olsen, Debra Breneman et al. · Clinical Lymphoma & Myeloma · 2009 · 97 citations

Medicine, Oncology, Pharmacotherapy +11

Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort

Megan Desai, Sareeta Parker · Journal of the American Academy of Dermatology · 2014 · 66 citations

Medicine, Oncology, Pathology +7